Quantum BioPharma announces promising results from its joint study with Massachusetts General Hospital, published in the European Journal of Nuclear Medicine and Molecular Imaging. The novel PET tracer demonstrated the ability to detect lesion differences in #MultipleSclerosis

3rd Party Article by MS News Today: multiplesclerosisnewstoday.com/news-posts/202… #Biotech #Nasdaq #QNTM #Multiplesclerosis #Neurodegenerative $QNTM

$QNTM

Most MS drugs require IV infusions. Lucid-MS is our small-molecule candidate, new chemical entity designed to be taken as a pill — aiming to address demyelination without the need for IV. #LucidMS #QNTM #MultipleSclerosis #Biotech $QNTM

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique

$QNTM #NASDAQ #Biotech #Multiplesclerosis

$QNTM #Nasdaq #Biotech #MS #Multiplesclerosis

Thank you for sharing your story Julie! #MSawareness #Multiplesclerosis

Third-Party Article on Quantum BioPharma's Lucid-MS Drug Candidate for Multiple Sclerosis. multiplesclerosisnewstoday.com/news-posts/202… #Multiplesclerosis #MS #Neurodegenerative #Brainhealth #Biotech #NASDAQ

What if MS treatment didn’t need injections? Lucid-MS: Oral. Targeted. Focused on Demyelination. Learn More : quantumbiopharma.com/lucid-ms News Recap August 11th globenewswire.com/fr/news-releas… #MS #Multiplesclerosis #Neurodegenerative #Neurology #Brainhealth #Demyelination #NASDAQ $QNTM

$QNTM

New Agoracom Article Covering Quantum BioPharma $QNTM tinyurl.com/yc6e8zuk

$QNTM

#MSawareness #Multiplesclerosis MS Canada A&W Canada

$QNTM

$QNTM

Check out our partners unbuzzd invest.unbuzzd.com

$QNTM

Why Multiple Sclerosis Affects More Women Than Men 3rd Party Article By WebMD webmd.com/multiple-scler… #Biotech #Nasdaq $QNTM